European Antibody Congress - Agenda Day 3

 

European Antibody Congress 2018, Day 3

08:00 Registration Opens

08:50 Conference doors open

World leading research

Chaired by TBC

09:20

Improving the effectiveness of anti-cancer mAb

If you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 207 092 1297
09:40

Fc-Optimized anti-CD25 depletes tumour-infiltrating regulatory T cells and synergizes with PD-1 blockade to eradicate established tumours

If you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 207 092 1297
Roland Kontermann
10:00

Bispecific and bifunctional fusion proteins

  • Concept of bispecific and bifunctional fusion proteins
  • Bispecific antibodies for dual targeting
  • Dual-acting costimulatory fusion proteins
  • Hexavalent death ligand fusion proteins
 

10:20 Networking refreshment break

Novel targets and biomarker discovery

Cutting-edge methods in antibody screening and immune repertoire sequencing

Computational antibody discovery and development

Research hub

Chaired by TBC

Chaired by Christoph Merten, Group Leader Microfluidics, European Molecular Biology Laboratory

Chaired by TBC

Chaired by Andreas Hougaard Laustsen, Postdoctoral Fellow, Tropical Pharmacology Lab, Technical University of Denmark

Antibody screening and immune repertoire sequencing
11:20

Universal allosteric switch modules to regulate antibody affinities

  • Antibody affinities in FACS were regulated by a linker-based allosteric effector domain
  • Validated with 5 different svFv so far
  • Works both in VH-VL / VL-VH orientation
  • Regulation under physiological conditions (no ion concentration change)
 
Computational discovery and development
11:20

Experimental and computational profiling of Biologics: a powerful duo for next generation developability

  • Early lead selection of biotherapeutics during preclinical development requires careful characterization of a variety of molecule properties to reduce the risk for encountering unexpected obstacles during technical development
  • Developability assessment at Novartis combines information about expression, aggregation propensity, process fit, stability, solubility, physicochemical properties, in vivo fitness and immunogenicity of potential candidates
  • This integrated approach prior to lead selection provides a thorough, yet resource efficient approach
 
Research hub
11:20

Antibody discovery and engineering in mammalian cells by homology-directed mutagenesis

  • Optimizing conditions for homology-directed mutagenesis in mammalian cells
  • Designing, generating, and analyzing synthetic antibody libraries
  • Full-length antibody screening and affinity maturation in mammalian cells
  • Deep mutational scanning in mammalian cells by combining homology-directed mutagenesis and deep sequencing
 
Novel targets and biomarker discovery
11:40

Reserved for Abcam

Antibody screening and immune repertoire sequencing
11:40

Deep sequencing analysis of phage selection outputs: Leaving conventional screening behind

  • We will show adaptations to library design and panning strategies exploiting the full potential of deep sequencing analysis of phage selection output pools to identify high affine antibodies without conventional screening
 
Computational discovery and development
11:40

A computational framework for predicting protein liabilities & improvement of antibody developability

  • AggScore: a new method to identify aggregation hotspots on the interaction surface of proteins by evaluating hydrophobic, but also charged surface patches
  • BioQSPR: a machine-learning suite to generate prediction models to address issues like aggregation, solubility, stability and viscosity
 
Research hub
11:40

Targeting the inside of the cell with antibodies

  • Approaches to target the inside of the cell
  • Knockdown of various membrane receptors with intrabodies
  • Intrabody mediated knockdown in mice
 
Antibody screening and immune repertoire sequencing
12:00

Reserved for AbCellera

Computational discovery and development
12:00

Reserved for supporting partner

If you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 207 092 1297
Research hub
12:00

Moving forward with adoptive transfer of expanded tumour-infiltrating lymphocytes (TIL) scientifically and in clinical practice

  • Determination of TIL quality and potential after initial harvesting
  • Effector phenotype of lymphocytes after excision and before infusion
  • Effect of serum and serum free medium on T lymphocytes
  • Timing and quantity of addition of antibodies to the TIL production
 
Julia Manzetti, PostDoc, Head of production of TILs, University Hospital Basel
Novel targets and biomarker discovery
12:20

Brain delivery and intracellular sorting of affinity variants of the anti-TfR antibody OX26

  • Antibody engineering has been used to create affinity variants of the mouse anti-rat transferrin receptor antibody OX26
  • We found an inverse correlation between antibody affinity and brain penetration, and efficacy in a model of inflammatory pain when coupled to the peptide galanin
  • Cell fractionation revealed the affinity variants had different intracellular fates, helping us understand how changes in affinity improve brain exposure
 
Antibody screening and immune repertoire sequencing
12:20

Droplet-microfluidics in antibody discovery and immunoncology

  • New 2-cell platform enabling the screening of antibodies for their effect on target cells
  • Compatible with difficult targets such as GPCRs
  • Complementary platform for the stratification of cancer patients for personalized treatments
  • Results are available within 24h after surgery/biopsy at very competitive screening costs
 
Computational discovery and development
12:20

Reserved for Supporting Partner

If you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 207 092 1297
Research hub
12:20

Design and development of mammalian cell perfusion cultures for end-to-end continuous biomanufacturing

  • Perfusion scale down model, Process development strategy
  • Improve media utilization efficiency
  • Process optimization
 
Novel targets and biomarker discovery
12:40

Towards a therapy of neurodegenerative diseases - a lesson learned from prion diseases

  • Neurodegenerative diseases
  • Prion diseases
  • Alzheimer's disease
  • Shed PrP, PrP226
  • Monoclonal antibody, scFv
  • BBB
  • Cell-penetrating peptide
 
 
Antibody screening and immune repertoire sequencing
12:40

MemoMAB: Antibody repertoires

  • Immune repertoire analysis and antibody discovery from human donors and animals
  • Repertoire biobanking in a screenable format using mammalian cell display
  • High fidelity and rapid turn-over times
 
Computational discovery and development
12:40

The sequence space of antibody repertoires

  • The sequence space that entire antibody repertoires cover is best investigated with large-scale networks
  • The sequence space architecture of antibody repertoires is reproducible, robust and redundant
  • Prospective on the predictability of evolutionary pathways in sequence space
 
Research hub
12:40

Highly homogeneous antibody modification through optimisation of the synthesis and conjugation of functionalised dibromopyridazinediones

  • Introduction to disulfide rebridging as a strategy for the synthesis of homogenous bioconjugates
  • Introduction to dibromopyridazinediones as a conjugation reagent for disulfide rebridging
  • Exploring optimal conjugation conditions for achieving maximum homogeniety across multi-disulfide systems (especially IgG1 Abs)
  • Exploring the effect of disulfide rebridging on antibody activity, with focus towards Fc interactions
 

13:00 Networking Lunch

Closing Keynotes

Chaired by Alain Beck, Senior Director, NBEs Analytical Chemistry, Pierre Fabre, Associate Editor, mAbs

Paul Carter
14:00

Antibodies as drugs: Pursuit of the ‘high hanging fruit’

  • Opportunities and challenges with antibody drugs
  • Applications of bispecific antibodies
  • Efficient production of bispecific IgG in single host cells
 
Partha Chowdhury
14:20

Evolution and advancements in cancer immunotherapy

14:20

Reserved for Supporting Partner

If you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 207 092 1297
15:00

Reserved for Supporting Partner

If you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 207 092 1297
15:25

Closing remarks from Terrapinn

15:30 - End of Congress

last published: 13/Jul/18 08:35 GMT

 

Mark Your Calendars Now!
Conference 29 - 31 October • Exhibition & Seminars 29 - 31 October 

Sign Up for Event Updates